Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Adaptimmune Therapeutics PLC (ADAP)  
$1.14 0.13 (12.87%) as of 4:30 Tue 4/23


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 154,660,000
Market Cap: 176.31(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $0.429 - $1.75
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Adaptimmune Therapeutics is a biopharmaceutical company focused on developing T-cell therapies for solid tumors. Co.'s proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. Co. has clinical trials on its ADP-A2M4, ADP-A2M4CD8, each targeting the MAGE-A4 antigen, and ADP-A2AFP SPEAR T-cells targeting the alpha fetoprotein (AFP) cancer antigen in solid tumor types including non-small cell lung cancer, head and neck cancer, ovarian, urothelial, melanoma, and hepatocellular.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 39,000
Total Buy Value $0 $0 $0 $11,326
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 0 165,799 218,930 354,372
Total Sell Value $0 $124,385 $172,782 $411,912
Total People Sold 0 4 5 6
Total Sell Transactions 0 16 19 41
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 234
  Page 1 of 10  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ecor1 Capital, Llc 10% Owner   –       –       •   2024-03-08 3 IO $0.00 $0 I/I 0 164,424,420 -44%     
   Norry Elliot Chief Medical Officer   •       –      –    2024-01-17 4 S $0.67 $12,300 D/D (18,276) 19,257 -35%     
   Lunger John Chief Patient Supply Officer   •       –      –    2024-01-17 4 S $0.67 $12,191 D/D (18,114) 19,015 -35%     
   Bertrand William C Jr Chief Operating Officer   •       –      –    2024-01-17 4 S $0.67 $12,725 D/D (18,908) 20,201 -35%     
   Rawcliffe Adrian Chief Executive Officer   •       •      –    2024-01-17 4 S $0.67 $20,244 D/D (30,080) 44,848 -35%     
   Norry Elliot Chief Medical Officer   •       –      –    2024-01-16 4 S $0.79 $1,807 D/D (2,287) 3,363 -38%     
   Lunger John Chief Patient Supply Officer   •       –      –    2024-01-16 4 S $0.79 $3,698 D/D (4,681) 7,023 -38%     
   Bertrand William C Jr Chief Operating Officer   •       –      –    2024-01-16 4 S $0.79 $3,698 D/D (4,681) 7,023 -38%     
   Rawcliffe Adrian Chief Executive Officer   •       •      –    2024-01-16 4 S $0.79 $7,350 D/D (9,304) 14,104 -38%     
   Lunger John Chief Patient Supply Officer   •       –      –    2024-01-12 4 S $0.85 $4,458 D/D (5,220) 7,874 -19%     
   Bertrand William C Jr Chief Operating Officer   •       –      –    2024-01-12 4 S $0.85 $4,458 D/D (5,220) 7,874 -19%     
   Rawcliffe Adrian Chief Executive Officer   •       •      –    2024-01-12 4 S $0.85 $14,739 D/D (17,257) 26,388 -19%     
   Norry Elliot Chief Medical Officer   •       –      –    2024-01-12 4 S $0.85 $6,661 D/D (7,799) 11,841 -19%     
   Lunger John Chief Patient Supply Officer   •       –      –    2024-01-11 4 S $0.84 $3,354 D/D (4,009) 6,104 -11%     
   Bertrand William C Jr Chief Operating Officer   •       –      –    2024-01-11 4 S $0.84 $3,354 D/D (4,009) 6,104 -11%     
   Rawcliffe Adrian Chief Executive Officer   •       •      –    2024-01-11 4 S $0.84 $9,994 D/D (11,945) 18,395 -11%     
   Norry Elliot Chief Medical Officer   •       –      –    2024-01-11 4 S $0.84 $3,354 D/D (4,009) 6,104 -11%     
   Lunger John Chief Patient Supply Officer   •       –      –    2023-08-01 4 S $0.91 $2,804 D/D (3,096) 4,718 37%     
   Menzel Garry E Director   –       •      –    2023-07-10 4 S $0.91 $43,447 D/D (47,702) 75,056 47%     
   Rawcliffe Adrian Chief Executive Officer   •       •      –    2023-06-27 4 S $0.92 $2,146 D/D (2,333) 3,519 39%     
   Menzel Garry E Director   –       •      –    2023-06-01 4 A $0.00 $0 D/D 209,931 209,931     -
   Menzel Garry E Director   –       •      –    2023-06-01 4 A $0.00 $0 I/I 401,293 200,647     -
   Piccina Cintia Chief Commercial Officer   •       –      –    2023-01-31 4 S $1.87 $22,230 D/D (11,890) 19,535 47%     
   Lunger John Chief Patient Supply Officer   •       –      –    2023-01-17 4 S $1.86 $8,250 D/D (4,440) 7,264 33%     
   Bertrand William C Jr Chief Operating Officer   •       –      –    2023-01-17 4 S $1.86 $8,250 D/D (4,440) 7,264 33%     
  234 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 10
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us